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A State and National Comparison of an Innovative
Neonatal Abstinence Syndrome Treatment Model
AU1c Lori Dickes, PhD,1 Julie Summey, EdD,2 Rachel Mayo, PhD,2 Jennifer Hudson, MD,3
Windsor Westbrook Sherrill, PhD,2 and Liwei Chen, MD, PhD, MHS2
Abstract
In recent years, neonatal abstinence syndrome (NAS) rates have increased rapidly across the United States,
rising from 1.2 (2000) to 5.8 (2012) per 1000 hospital births annually. Because most NAS infants are treated in
an intensive care setting, associated hospital charges are high and continue to escalate, rising on average from
$39,400 in 2000 to $66,700 in 2012. An innovative NAS treatment program, which includes early-initiated
methadone therapy, rooming-in, and combined inpatient/outpatient weaning in a low-acuity nursery, has been in
place since 2003 at a large Southeastern hospital. The program has proven safe, effective and low cost for
treating infants of ‡35 weeks gestational age whose mothers used long-acting opioids. Given that 81% of NAS
cases in the United States are funded by Medicaid programs and that the cost burden is rising rapidly,
researchers considered the potential saved charges associated with implementing the same program in other
hospitals state- and nationwide. Researchers used regression models to project state and national NAS birth
rates from 2015–2025 and to predict future NAS charges under current treatment protocols. Three scenarios
were developed to compare the potential saved charges of implementing the innovative NAS treatment program
across the state and nation with assumptions related to the percent of NAS infants eligible for the program,
percent funded by Medicaid, and fluctuations in average length of stay. The potential saved charges are
substantial, creating a compelling case for policy makers and hospitals in the pursuit of safe, effective, and cost-
conscious NAS care.
Keywords: neonatal abstinence syndrome, Medicaid, cost savings
IAU3c ntroduction
Neonatal abstinence syndrome (NAS) results when anewborn is born dependent on substances used by a
mother during pregnancy.1 In recent years, NAS rates have
increased rapidly across the United States, rising from 1.2
(2000) to 5.8 (2012) per 1000 hospital births annually.2,3
With approximately 4 million births in the United States
annually, more than 23,000 babies are expected to be diag-
nosed with NAS per year.4
The NAS epidemic is a significant public health problem
both because of the severity of the neonate’s medical
withdrawal experience and because the majority of NAS
cases are covered by Medicaid, a publicly provided state
health insurance program.2–8 Because many infants are
managed in neonatal intensive care unit (NICU) environ-
ments, hospital charges for NAS care are increasing na-
tionally. Patrick et al. estimated that the mean US hospital
charges per infant discharged with NAS rose from $39,400
in the year 2000 to $66,700 in 2012.2,3 In addition, 2012
data show that pharmacologically-treated NAS infants had
mean hospital charges totaling $93,400 and a mean length of
stay of 23 days.3 With an estimated 23,000 NAS infants
born annually, charges would total $1.5 billion on average.
Medicaid was the primary payer for 81% of cases.3
Medicaid typically reimburses approximately 50% of hos-
pital charges. Data comparing reimbursement rates for NAS
between states was not available, and national literature
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reporting the financial impact of NAS care is framed in
terms of charges, so the figures presented in this paper will
be in hospital charges for consistency. With the expansion
of Medicaid in some states and the addition of the Chil-
dren’s Health Insurance Program (CHIP) across all states,
the vast majority of infants born in the United States are
covered by some health insurance policy at birth.9,10 Federal
law allows for considerable flexibility in how individual
states manage Medicaid reimbursement. According to the
Medicaid and CHIP Payment and Access Commission, there
are 3 broad categories of Medicaid reimbursement ap-
proaches: per diem, cost reimbursement, and flat rate pay-
ment based on diagnosis-related groups (DRGs).11 In 2004,
there was advisement from the Centers for Medicaid &
Medicare Services (CMS) that states implement more up-to-
date payment methods or develop their own.12 As such,
many states now use a range of algorithms that reimburse
hospitals based on DRGs. The move toward reimbursement
based on DRGs is argued to be an important step in pro-
viding more efficient and cost-effective care.13,14 Currently
in South Carolina, Medicaid reimbursement is per diem for
pediatrics but uses a CMS-DRG algorithm for other hospital
stays.12 Given the ongoing evaluation of Medicaid reim-
bursement and policy pressures to improve effectiveness
while stabilizing or reducing costs, it is likely that South
Carolina and other states will move to a DRG model for
pediatric care in the future.
Geographic variation in incidence across the nation also
has been documented. The state of South Carolina falls into
one of the country’s geographic regions with the highest
NAS incidence rates.3 In South Carolina, the NAS rate was
6 per 1000 newborns in 2013 compared to 3 per 1000 in
2010.15 Average hospital charges for an NAS newborn in
the state were $39,110 in 2013 with an average length of
stay of 12.4 days compared to an average of 3.7 days for all
state newborns.15
As states evaluate the allocation of Medicaid funds, the
substantial cost burden associated with existing NAS care
provides opportunities for states to consider innovative treat-
ment methods. Concerns over rising health care costs, partic-
ularly those financed by public payers, provide an impetus to
examine the potential cost savings of new treatment programs.
Few studies have examined the potential effectiveness of
hospital-level interventions related to NAS treatment; how-
ever, examples of 2 interventions that have been developed and
tested separately include rooming-in care with mothers and
combined inpatient/outpatient weaning programs.16–21
Considering the number of population health challenges
associated with increasing opioid use, new treatment pro-
grams that combine improved patient outcomes with cost-
effective care must be explored. The Managing Abstinence
in Newborns (MAiN) program, an innovative method of
NAS treatment, has been developed at Greenville Memorial
Hospital (GMH), a large, regional Southeastern hospital. For
otherwise healthy newborns at high risk for opioid with-
drawal, the treatment program includes early-initiated
methadone treatment (within 24 hours of birth), rooming-in
with mothers in a low-acuity care setting, and a combined
inpatient/outpatient methadone wean.22 Using state and
national data related to NAS cases, the researchers propose
different scenarios of potential future saved charges through
use of this innovative NAS treatment program. This research
has relevance for hospitals, Medicaid, and other payers as
well as public policy makers.
Methods
Early treatment program description
The MAiN program was developed in 2003 at GMH-a
large (710 beds), regional hospital that is part of a public,
not-for-profit academic health care delivery system. GMH
experienced an average annual volume of 5221 births from
2006–2014, with approximately 88% of newborns admitted
to the mother/baby unit. The MAiN treatment program is
based on the theory that neonates who are chronically exposed
to long-acting opioids in late gestation are born dependent,
because research has demonstrated significant transfer of
opioids across the placenta.23 When started within 24 hours of
birth, low-dose methadone may be considered a continuation
of long-acting opioid therapy and therefore prevent severe
opioid withdrawal and its complications.
To be eligible for the MAiN treatment model, a neonate
must be born to a mother who has been taking at least 20 mg
of methadone or at least 9 mg of buprenorphine for at least 2
weeks immediately prior to delivery. In addition, the neo-
nate must be at least 35 weeks gestational age and have no
other conditions at birth that would require intensive care.
Between 2006 and 2014, 472 NAS-diagnosed infants were
born at GMH, and approximately 30% of these infants met
the MAiN eligibility criteria. The other 70% were excluded
as follows. Ninety-three infants (20%) were admitted to
neonatal intensive care immediately after delivery for ges-
tational age <35 weeks and/or ill appearing at birth. Me-
thadone was never administered to 201 of the infants (43%)
who were exposed in utero to unknown or non-opioid
substances. Methadone was initiated after 48 hours of birth
in 35 of the infants (7%) because of parent opposition to
early treatment or physicians assessed risk of withdrawal
as low but symptoms later became severe enough to war-
rant treatment. A total of 143 patients (30%) were eligible
for MAiN, but 26 patients (5%) had to later be transferred
to neonatal intensive care for medical illness or compli-
cation. Hence, 117 infants (25%) completed the MAiN
treatment model.
In the MAiN model, neonates admitted to the low-acuity
mother/baby unit whose mothers are taking chronic long-
acting opioids are offered early pharmacologic treatment,
breastfeeding support (unless contraindicated), and extended
maternal stay for the duration of the birth hospitalization.
All neonates are managed by a pediatrician and receive low-
stimulation supportive care. Within 24 hours of birth, infants
exposed to maternal methadone doses of 60 mg or higher are
started on 0.1 mg/kg/dose of methadone every 6 hours; those
exposed to less methadone or to buprenorphine are started
on 0.05 mg/kg/dose every 6 hours. Urine and meconium
drug screening and prescription monitoring database queries
are performed routinely. Continuous monitoring for apnea
and bradycardia is provided in the mother’s room, and
modified Finnegan scoring is performed every 4 hours by
trained mother/baby nursing staff. A social work evaluation
is completed for all families. Any feeding supplementation,
whether by maternal choice or physician order, is initiated
with expressed breast milk or standard 20 kcal/oz. formula.
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Once an infant meets criteria for discharge, a weaning
calendar is developed by a pediatric pharmacist, and meth-
adone is dispensed in pre-filled oral syringes from the hos-
pital outpatient pharmacy at an average out-of-pocket cost
to the family of $13 per 1-month supply. Medicaid does not
cover the cost of the infant’s prescription in South Carolina.
Caregivers are required to fill the prescription prior to dis-
charge, and unit staff reconcile that all necessary syringes
have been dispensed and that caregivers understand how to
administer medication per program instructions.
During the outpatient weaning period, dosage reductions
of approximately 15% (of the discharge dose) occur every
Sunday and Wednesday for approximately 4 weeks. Office
visits occur weekly at an outpatient pediatric medical home
during weaning to evaluate the effect of medication reduc-
tion. Outpatient physicians assess for signs or symptoms of
poor NAS control and have the option to slow the weaning
process if necessary. During the outpatient methadone wean,
each infant generates an additional $655 in outpatient
charges beyond a normal infant. Hospital inpatient social
workers collaborate with social workers in the pediatric
medical home to ensure that transportation needs are met
and follow-up is ensured for weaning visits. Outpatient so-
cial workers closely track visit compliance and address
cases of concern. One or 2 postpartum newborn home visits
are routinely provided by South Carolina Department of
Health and Environmental Control for all families with
Medicaid through a local health department. Families with a
weaning infant receive targeted education and evaluation
during these encounters. No new costs are generated by
utilizing the home visiting program. Once completely off
medication, infants are followed according to the re-
commended Early and Periodic Screening, Diagnostic, and
Treatment schedule. All newborns are referred for formal
developmental assessment at 3–4 months of age as well as to
phone-based parenting support and developmental screening
services (Help Me Grow) that are available until the child
reaches age 8.
Initial evidence for the MAiN treatment program reveals
that it is safe, effective, and results in substantial cost
savings compared to national expenditures for NAS in-
fants.15 A retrospective study was conducted to evaluate
the MAiN program. From 2006–2014, 143 patients were
enrolled in MAiN at GMH. Because of medical illness or
complication, 26 patients (18%) were transferred to the
NICU after enrollment, and 117 patients (82%) completed
the inpatient component of the MAiN treatment program.
Infants in the MAiN program from 2006–2014 experienced
a median peak weight loss of 7% (range: 1% -14%) and
median peak modified Finnegan score of 10 (range: 3–21).
The overall breastfeeding rate among the cohort was 42%.
Five newborns (4%) experienced oversedation. There were
no medication errors, seizures, or deaths. Outpatient re-
cords were available for 115 patients. Of these, 14% vis-
ited an emergency department within 30 days of discharge;
7% were readmitted, none with a primary diagnosis of
withdrawal. This may represent a significant improvement
over standard treatment for NAS, during which infants
often are treated in a NICU environment. In addition to
improved patient outcomes, widespread implementation of
the MAiN program may result in significant savings in
hospital charges.
Data
Data collection for infants treated with MAiN at GMH was
performed through data extraction from electronic medical
records and direct chart review. All data were abstracted by a
trained research assistant. Additional data on South Carolina
NAS infants were acquired from all-payer inpatient hospitali-
zation and emergency department encounter data, linking with
state birth certificate and Medicaid claims data. This study
population included all infants born in South Carolina hospitals
between 2006 and 2014. NAS infants were identified using
International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) codes of 779.5 and/or
760.72. The ICD-9-CM code 779.5 describes ‘‘drug with-
drawal syndrome in newborn,’’ and the ICD-9-CM code
760.72 identifies ‘‘narcotics affecting fetus or newborn via
placenta or breast milk.’’ Statistical analyses were performed
using Stata 14 (StataCorp LP, College Station, TX, US).
Economic impact analysis description
A multistep approach was utilized to develop a cost analysis
of the potential state and national saved charges that might
result from widespread implementation of the MAiN treatment
model. Researchers first identified the number of NAS cases in
South Carolina for each year from 2006–2014 and the number
of total births for the state over the same period. These data
were then used to develop an annual NAS case rate per 1000
births. A linear regression model with case rate as the depen-
dent variable and year as the independent variable was gener-
ated to predict the NAS case rate per 1000 births for South
Carolina from 2015–2025. The NAS case rate per 1000 births
for the years 2015–2025 was multiplied by the projected
number of births per year in each of those years to obtain the
projected number of NAS cases per year. State projected births
for 2015–2025 were acquired from the South Carolina Revenue
and Fiscal Affairs Office - Health and Demographics Section.
From 2006–2014, 25% of NAS infants at GMH were
treated by the MAiN model. The researchers maintain this
assumption that 25% of NAS infants will meet eligibility
criteria for the MAiN model to obtain the projected number
of MAiN-eligible infants for South Carolina. Recent Ten-
nessee data confirmed that more than 50% of NAS cases
were from supervised maternal opioid treatment therapy.25
The present study’s 25% estimate is conservative, given the
data from Tennessee.
Using retrospective charge data for the MAiN program
and the state, additional linear regression models were
generated to predict NAS-related charges from 2015–2025.
Several model estimations were tested for best fit and sig-
nificance. After exploring these other model options, linear
regression proved to be the best model fit across the sce-
narios. Data met the assumptions for linear regression. A
time series model was not appropriate because of data
limitations. Length of stay (LOS) was determined to be the
key predictor of NAS charges. The final model included
annual mean LOS as the independent variable and annual
mean hospital charges as the dependent variable.
Scenario narratives
Three scenarios were developed to estimate the potential
fiscal impact of widespread implementation of the MAiN
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program based on assumptions related to LOS as well as
state and national MAiN and Medicaid eligibility.
Scenario 1 assumes that all future charges are based on
the same average LOS demonstrated over the time period
2006–2014. It further assumes that 25% of NAS cases will
be eligible for the MAiN program and that 80% of infants
are covered by Medicaid, which is comparable with national
literature.2,3
Scenario 2 takes into account variability in LOS because
of the strong relationship between LOS and total charges.
LOS for state NAS cases showed a mean annual increase
from 2006–2014 of 4.94% and was highly variable from
year to year, with a total inflation-adjusted change over the
time period of 13%. The mean annual change in LOS for the
MAiN program was 1%, which was relatively stable over
the time period. Given the variability in state LOS and the
short time series, the researchers assume a conservative 2%
annual increase in LOS for the state and a 1% increase in
LOS for the MAiN program. The predicted mean LOS over
the 11-year period 2015–2025 is used to estimate future
charges for statewide cases and for those managed with the
MAiN program. This assumption presumes the current per
diem reimbursement model for Medicaid infants. If South
Carolina were to shift to a DRG reimbursement model, LOS
would not be relevant for this analysis. This model retains
the assumption that 25% of NAS infants are MAiN eligible
and 80% of infants are consistently funded by Medicaid.
Scenario 3 proposes that the MAiN program is im-
plemented on a national scale. Assuming current national
growth trends in NAS rates, a linear regression model was
used to estimate future NAS rates per 1000 births. Using
national projections of US birth rates and estimated NAS
rates, future NAS births were projected. An equation to
predict national NAS charges was developed with LOS as
the independent variable. This analysis retains the assump-
tion that 25% of NAS infants are MAiN eligible and 80% of
infants are consistently funded by Medicaid. With these
metrics in place, the researchers assess the potential savings
in hospital charges if the MAiN program were implemented
on a national scale. These estimates do not account for ap-
proximate Medicaid reimbursement rates and as such must
be considered an upper bound of potential savings.
Results
Patient data were collected on 117 infants receiving the
MAiN treatment model at GMH from 2006–2014.F1c Figure 1
illustrates the mean hospital charges per NAS case for in-
fants treated with the MAiN program as well as mean
hospital charges for all NAS cases in the state and nation.
All charges were adjusted to 2014 USD (US dollars). Using
analysis of variance to test difference in means, results re-
veal a statistically significant difference in charges between
the MAiN population and the state and national populations
(P < 0.0001). From 2006–2014, average charges for NAS
infants in the MAiN program at GMH were $10,946.96
(2014 USD) compared to an average of $44,544.17 (2014
USD) for NAS infants statewide and $59,641.35 (2014
USD) for NAS infants nationwide.
From 2006–2014, mean hospital charges for NAS infants
treated in the MAiN program were relatively stable, with a
mean annual change of 1.9% per year. Mean annual state
charges for NAS diagnosed infants increased approximately
7.24% per year. From 2006 to 2014, total inflation-adjusted
charges increased 12.17% for NAS infants treated with
MAiN and 63.7% for NAS infants statewide. From 2000–
2012, the total inflation-adjusted change in NAS-related
charges nationally was 26.97% with an annual average in-
crease of 4.5% over the 13-year study period.
County and state NAS birth projections
A linear regression model was used to test for model
significance and prediction of future NAS cases in South
Carolina. The dependent variable was NAS rate per year
(2006–2014), and the independent variable was year. The
model has an R2 of 0.93, with 93% of model variation
predicted by this model. bT1Table 1 contains the projected
number of NAS births and MAiN treated infants in South
Carolina in 2015, 2020, and 2025.
These results confirm the potential for a substantial in-
crease in the number of NAS diagnosed infants from 2015
through 2025. For South Carolina, the researchers predict a
6% increase in total births and a 99% increase in NAS cases
if current trends hold. If the MAiN program continues to
apply to approximately 25% of NAS diagnosed infants,
substantially more state infants could be treated with this
intervention.
County, state and national NAS charges projections
The following models were estimated to predict annual
mean hospital charges for the MAiN program and the state.
These prediction models use a fixed annual mean LOS,
calculated as the mean of the annual average LOS over the
time period.
FIG. 1. Average inpatient charges for NAS infants, 2006–
2014. NAS, neonatal abstinence syndrome.
b 4C
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(1) MAiN : Y ¼ 3881:66þ 849:91  annual mean LOSð Þ
Adjusted R2 ¼ 0:44
(2) South Carolina : Y ¼  27032:39
þð5733:15  annual mean LOSÞ
Adjusted R2 ¼ 0:83
Using predictions of NAS births and estimated charges,
the following 3 scenarios explore potential saved hospital
charges for state Medicaid programs and state and national
taxpayers that support these safety net programs.
Scenario 1.T2c Table 2 presents results of the 3 scenarios.
Scenario 1 uses equations (1) and (2) and assumes a fixed
annual mean LOS of 8.27 days for MAiN and 12.85 for the
state (i.e., the same average LOS from 2006–2014). The results
of this scenario show that over the 11-year time period 2015–
2025, the saved charges are estimated to exceed $56,000,000.
Scenario 2. Scenario 2 uses equations (1) and (2) and
assumes a mean annual LOS of 9.32 days for MAiN and
14.67 days for the state based on the 1% and 2% projected
annual increase in LOS, respectively. Based on these equa-
tions, predicted charges for MAiN are $11,802.82 per case,
and predicted charges for the state are $57,072.92 per case.
Scenario 2 results reveal average state charges for these
11 years of $89,607,241 with no intervention (Table 2).
From 2015–2025, a statewide MAiN program expansion
could reduce charges to state Medicaid by more than
$71,000,000.
Scenario 3. Scenario 3 estimates potential nationwide
saved charges if the MAiN program were to be implemented
on a national scale. The average NAS rate per 1000 births
from 2000–2012 was 3.39 births per 1000. Using the fol-
lowing linear regression model (3) to estimate the future
NAS case rate for the United States and applying that rate to
the number of births projected by the US Census,17 the
number of future neonates with NAS is estimated to be
25,746 in 2015, 34,727 in 2020, and 43,474 in 2025.
(3) Y ¼  791:3þ 0:3959  YEARð Þ
Adjust R2 ¼ 0:89
Over the 11-year period from 2015–2025, 381,358 infants
could be diagnosed with NAS. By 2025, applying the 25%
treatment eligibility assumption, almost 11,000 infants per
year across the United States could be eligible for the MAiN
treatment program, with an approximate total of 95,000
infants eligible for MAiN across the US from 2015–2025.
National data reveal an average LOS of 16.3 days from
2000–2012, with average national charges of $59,641.35 per
NAS case (2014 USD). The regression model used to pre-
dict national charges (adjusted to 2014 USD) is given by (4):
(4) Y ¼  38604þ 6022  annual mean LOSð Þ
Adjusted R2 ¼ 0:55
Using current treatment protocols and assuming a fixed
16.3-day LOS, total charges are estimated to be more than
$4.5 billion for approximately 76,000 infants treated across
the nation from 2015–2025.
Equation (1) was used to estimate national charges if
MAiN were expanded across the United States. Assump-
tions included that 25% of NAS infants would be eligible for
MAiN, 80% of MAiN-eligible infants would be covered by
Medicaid, and the LOS would be fixed at 8.27 days. Results
show that if MAiN were expanded, the average savings is
projected to be more than $337 million annually in Med-
icaid charges, with a total potential reduction in Medicaid
charges of approximately $3.7 billion from 2015–2025.
Discussion
Currently, a national standard treatment protocol for NAS
infants does not exist in the United States. Although some
innovative treatments are described in the literature,16–21
NAS-diagnosed infants are largely treated in NICUs across
the country. As health care systems transition away from fee
for service to population-based reimbursement for care,
there is incentive for hospitals to consider lower cost, ef-
fective treatment models. In this case, hospitals that have
implemented low-cost solutions for NAS care will save
money as well. Thus, from a clinical perspective, there is
impetus to explore innovative treatments, and as these
treatments are proven safe and efficacious, understanding
the cost-effectiveness of these models is critical.
This analysis illustrates that there are strong cost incentives
related to implementing the MAiN program across the state
and nation. Each of the described scenarios makes conser-
vative assumptions about current trends that may or may not
occur; however, if current trends continue with little change
to the current NAS treatment protocol, the cost burden to
Medicaid and hospitals will increase and may increase sub-
stantially. Further, LOS assumptions inherent in this analysis
would be of little importance if the state, and others, shift to a
DRG reimbursement model for pediatric care.
Table 1. South Carolina Projected Neonatal Abstinence Syndrome Births and Managing
Abstinence in Newborns-Eligible Infants
Year
NAS case rate
per 1000 births
Projected number
of total births
Projected number
of NAS cases
Projected number of
MAiN-eligible infants
2015 8.35 57,540 480 120
2020 12.00 59,140 710 177
2025 15.65 61,180 957 239
2015–2025 — 651,860 7850 1963
Prediction equation: y = 0.7299x-1462.4.
MAiN, Managing Abstinence in Newborns; NAS, neonatal abstinence syndrome.
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It is important to note that this analysis does not take
into account the costs of implementing a new treatment
model; however, based on information from the reference
hospital, these costs are not necessarily substantive and in
many cases would not require hiring additional staff. Much
of the implementation requires training existing staff to
regularly, appropriately monitor NAS infants, providing
consultation and education for families, establishing part-
nerships with supportive community resources, and po-
tentially hiring a case manager depending on the caseload
of NAS infants.
Additional limitations of this study include that the MAiN
model is a program for NAS infants at high risk for with-
drawal related to long-acting opioid exposure, whereas the
state and national cohorts are composed of all NAS infants.
Infants coded for NAS in these cohorts may have been af-
fected by a variety of medications or illicit drugs used by a
mother as prescribed or illegally. Others may have been
coded for NAS because of withdrawal from medications
administered to the neonate during prolonged critical illness.
Recent research from the state of Tennessee provides evi-
dence that more than half of all 2015 NAS cases were as-
sociated with supervised opioid replacement therapy.25 The
initial study population led to the conservative assumption
that 25% of NAS infants in the state and national cohorts
would be eligible for MAiN; however, recent research may
indicate MAiN may have wider application.
The analyses in this study were limited to using hospital
charges to estimate saved charges to Medicaid, because state
and national cost data were not available. Charges do not
account for Medicaid reimbursement rates, which in South
Carolina range from 40% to 50% for NAS infants depending
on whether infants receive treatment in a NICU or non-
NICU setting. As such, these estimated saved charges
should be considered as a first step in examining the po-
tential economic magnitude of an innovative treatment
model such as MAiN.
The challenge of NAS continues to be discussed and
evaluated on a national scale. Although opportunities for
more effective treatment should be considered across the
nation, there are outpatient methadone policy differences
from state to state and even within states that may prove to
be barriers to replication of innovative treatments.26–28 Al-
though states are obligated to meet national regulatory
standards, states and localities may exceed federal minimum
standards. For example, some states do not allow patients to
be discharged on drugs such as morphine or methadone, an
important component of the MAiN intervention. Other
dosing requirements vary across states, and some states may
automatically withdraw a pregnant patient from methadone
treatment. All of these variations in policy among others
make a standard national treatment protocol difficult to
implement in the near term.26,28
As NAS research continues, a more robust time series of
data is an important area for future research consideration.
The MAiN program treated 117 infants from 2006–2014, and
small sample sizes in some years could have impacted overall
model results. Further, as researchers continue to examine
this issue, better understanding of the socioeconomic patterns
of mothers and NAS infants, the geographic distribution (e.g.,
Table 2. Estimated State and National Savings of Managing Abstinence in Newborns Neonatal
Abstinence Syndrome Treatment Model Expansion
Scenario 1: 25% MAiN eligibility and 80% Medicaid coverage
Year
State MAiN-eligible
infants (from Table 1)
State infants covered
by Medicaid (80%)
Total charges-no
intervention
Total Medicaid
charges with intervention
Charge
savings
2015 120 96 $4,480,781 $1,048,214 $3,432,567
2020 177 142 $6,618,592 $1,548,323 $5,070,268
2025 239 191 $8,929,555 $2,088,940 $6,840,616
2015–2025 1963 1570 $73,224,839 $17,129,886 $56,094,952
Scenario 2: 25% MAiN eligibility, 80% Medicaid coverage, annual length of stay increase of 2% for State
(no intervention) and 1% for MAiN (intervention)
State MAiN-eligible
infants (from Table 1)
State infants covered
by Medicaid (80%)
Total charges-no
intervention
Total Medicaid
charges with intervention
Charge
savings
2015 120 96 $5,483,254 $1,133,950 $4,349,304
2020 177 142 $8,099,352 $1,674,966 $6,424,386
2025 239 191 $10,927,342 $2,259,801 $8,667,541
2015–2025 1963 1570 $89,607,241 $18,530,997 $71,076,243
Scenario 3: 25% National eligibility and 80% Medicaid coverage
Year
National MAiN-eligible
infants
National infants covered
by Medicaid (80%)
Total charges-no
intervention
Total Medicaid
charges with intervention
Charge
savings
2015 6436 5149 $306,656,439 $56,179,549 $250,476,891
2020 8682 6945 $413,628,546 $75,776,870 $337,851,676
2025 10,869 8695 $517,816,648 $94,864,160 $422,952,488
2015–2025 95,339 76,272 $4,542,321,892 $832,154,688 $3,710,167,203
MAiN, Managing Abstinence in Newborns; NAS, neonatal abstinence syndrome.
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urban vs. rural) of NAS, along with policy impacts across
states are all important areas of future research.
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